Glaxo hails 'important milestone' for HIV drug

Drugs giant GlaxoSmithKline has reported positive results from an initial study into its development of a drug for HIV treatment.

ViiV Healthcare, a global HIV firm established by Glaxo and Pfizer, and Shionogi & Co announced this morning that the SPRING-2 (ING113086) - the Phase III study of the investigational integrase inhibitor dolutegravir in treatment-nave adults with HIV-1 - met its primary objective, showing non-inferiority of dolutegravir to raltegravir.

"The SPRING-2 findings indicate that once daily unboosted dolutegravir may offer people living with HIV an additional treatment option in the future," sid ViiV's Chief Medica Officer John Pottage.

Start your trial of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up

"These are the first large-scale safety and efficacy data in nave patients, and we look forward to seeing further data in 2012 to build a more comprehensive picture of the role of dolutegravir," he said.

During a period of 48 weeks, 88% of study participants on the one-daily drug were "virologcially supressed" compared with 85% of participants on raltegravir (twice daily).

Shionogi & Co's Chief Executive Officer, Tsutae Nagata, said that the findings mark an "important milestone" for dolutegravir and the Shionogi-ViiV joint venture.

BC